Compare Cassava Sciences Inc (FLNA) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Alphabet Inc Class A — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Alphabet Inc Class A trades at $351.07 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 107614.2× Cassava Sciences Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Alphabet Inc Class A for 85 Days on average.
| FLNA | GOOGL | |
|---|---|---|
Market Cap | $39.40M | $4.24T |
Volume | 759,018 | 23,392,850 |
Sector | Health | Media |
52-Week High | $4.64 | $402.62 |
52-Week Low | $0.68 | $236.59 |
Typical Hold Time | 37 Days | 85 Days |
Enterprise Value | -$43.28M | $4.13T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
GOOGL trades at $350.50, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats. Recent news highlights AI-driven growth opportunities through partnerships with Anthropic and SpaceX, while YouTube's subscription price increases signal revenue diversification. Analyst consensus remains overwhelmingly positive with 87% buy ratings.
Outlook remains favorable given strong fundamentals and AI leadership, though regulatory risks and market volatility present challenges. The $431.83 consensus price target implies 23% upside potential. Investment opportunity centers on sustained AI monetization and cloud growth, balanced against antitrust scrutiny and competitive pressures in digital advertising.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
